A method for culturing the infectious stage of the Plasmodium lifecycle could increase malaria vaccine production efficiency by tenfold, study authors say.
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.